ReviewDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2020
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
Review in Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04602507 (Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial), which is not on this map. Cited by 89 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial
Who cites it
89 citing papers in PubMed, 2 syntheses or guidelines pooled it, 188 citations in OpenAlex.
- Global distribution of ACE1 (rs4646994) and ACE2 (rs2285666) polymorphisms associated with COVID-19: A systematic review and meta-analysis.Microbial pathogenesis · 2022Pooled it
- A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.Drug design, development and therapy · 2022Pooled it
- Fisetin as an Antiviral Agent Targeting the RNA-Dependent RNA Polymerase of SARS-CoV-2: Computational Prediction and In Vitro Experimental Validation.Microorganisms · 2025Article
- Identification of effective synthetic molecules against viral-induced cytokine release syndrome using in silico and in vitro approaches.Molecular diversity · 2025Article
- Insights from integrated covalent docking and molecular dynamics simulations of nirmatrelvir analogs as potential SARS-CoV-2 MScientific reports · 2025Article
- An exploratory binding study of molnupiravir efficacy against emerging Omicron SARS-CoV-2 variants.Scientific reports · 2025Article
- Eco-friendly spectrofluorimetric determination of remdesivir in the presence of its metabolite in human plasma for therapeutic monitoring in COVID-19 patients.Scientific reports · 2025Article
- Sulfonohydrazide as a potential inhibitor of SARS-CoV-2 infection.Scientific reports · 2025Article
- The Binding of Brazilin fromInternational journal of molecular sciences · 2025Article
- Traditional Chinese Medicine for Viral Pneumonia Therapy: Pharmacological Basis and Mechanistic Insights.International journal of biological sciences · 2025Review
- Identification of Potential FDA-Approved Inhibitors of SARS-CoV-2 Helicase Through a MultistepMedicinal chemistry (Shariqah (United Arab Emirates)) · 2025Article
- Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial.BioImpacts : BI · 2025Article
- Recent Advancements in the Delivery of Therapeutic Agents Targeting RNA-dependent RNA Polymerase of SARS-CoV-2.Current medicinal chemistry · 2025Review
- Design, Synthesis and Biological Exploration of NovelInternational journal of molecular sciences · 2024Article
- Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.Molecules (Basel, Switzerland) · 2024Review
- Association between selective serotonin reuptake inhibitors and mortality following COVID-19 among patients with Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2024Article
- Phytoconstituents of Artemisia Annua as potential inhibitors of SARS CoV2 main protease: an in silico study.BMC infectious diseases · 2024Article
- Therapeutic Management with Repurposing Approaches: A Mystery During COVID-19 Outbreak.Current molecular medicine · 2024Review
- Antibiotics Prescriptions Pattern among Patients Visiting Primary Health Care Centers (PHCC) before and during COVID-19 Pandemic: A Cross-Sectional Population-Based Study from Qatar.Antibiotics (Basel, Switzerland) · 2023Article
- In Silico Design of New Dual Inhibitors of SARS-CoV-2 MInternational journal of molecular sciences · 2023Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-threatening pneumonia in the Hubei province, China, and has now spread worldwide, causing a pandemic. The urgent need to control the disease, combined with the lack of specific and effective treatment modalities, call for the use of FDA-approved agents that have shown efficacy against similar pathogens. Chloroquine, remdesivir, lopinavir/ritonavir or ribavirin have all been successful in inhibiting SARS-CoV-2 in vitro. The initial results of a number of clinical trials involving various protocols of administration of chloroquine or hydroxychloroquine mostly point towards their beneficial effect. However, they may not be effective in cases with persistently high viremia, while results on ivermectin (another antiparasitic agent) are not yet available. Interestingly, azithromycin, a macrolide antibiotic in combination with hydroxychloroquine, might yield clinical benefit as an adjunctive. The results of clinical trials point to the potential clinical efficacy of antivirals, especially remdesivir (GS-5734), lopinavir/ritonavir, and favipiravir. Other therapeutic options that are being explored involve meplazumab, tocilizumab, and interferon type 1. We discuss a number of other drugs that are currently in clinical trials, whose results are not yet available, and in various instances we enrich such efficacy analysis by invoking historic data on the treatment of SARS, MERS, influenza, or in vitro studies. Meanwhile, scientists worldwide are seeking to discover novel drugs that take advantage of the molecular structure of the virus, its intracellular life cycle that probably elucidates unfolded-protein response, as well as its mechanism of surface binding and cell invasion, like angiotensin converting enzymes-, HR1, and metalloproteinase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.